The durability of responses and new signals of long-term adverse events showed here, as well as previous report of a high early response rate, support that donor-derived CD7 CAR T cells may be a feasible salvage treatment for children or adults with r/r T-ALL. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.